Objective: Endometrial carcinoma (EC) is the most common cancer of the female genital tract. According to the recently evolved strategies of cancer immunotherapy, immune checkpoints inhibitors are one of the most crucial strategies. Programmed Death Ligand 1 (PD-L1) is an important immune checkpoint regulator. PD-L1 antibodies have shown efficacy in clinical trials of some malignancies. Some of these antibodies have been approved for clinical usage by the Food and Drug Administration (FDA). Methods: This retrospective study included a total of 100 ECs, collected from archived, formalin-fixed, paraffin-embedded tissue blocks of hysterectomy specimens of Egyptian females. The samples were immunohistochemically analyzed for PD-L1 expression (in both tumor cells; TCs and tumor infiltrating leucocytes; TILs) by a semiquantitative score (0 to 4), with cutoff points of (0: <1% of the cells, 1: 1% to 4%, 2: 5% to 9%, 3: 10% to 49%, and 4: ≥ 50%). Membranous staining only was considered positive. Results: PD-L1 was highly expressed in ECs (67% TCs+ and 61% TILs+), with statistically significant relationships with age, lympho-vascular space invasion (LVSI) and TILs score (P = 0.006, 0.016 and <0.005 respectively). However, no statistically significant relationships were detected between PD-L1 expression and the following parameters: histological type, histological grade, pathological stage (pT) or FIGO stage, myometrial, cervical, adnexal/serosal, parametrial involvements and nodal metastasis, as well as ESMO risk stratification system. Moreover, statistically significant relationships were achieved when correlating TILs score with tumor grade and LVSI (P = 0.034 and 0.012 respectively). Also, comparing endometrial hyperplasia (EH) PD-L1 and TCs PDL1 median scores achieved statistically significant relationship (P = 0.001). Conclusion: Our results concluded that PD-L1 expression was greater in both TCs and TILs in a subgroup of patients that have advanced age, LVSI and are TILs-rich, identifying them as potential candidates for anti-PD-1/PD-L1 immunotherapy.
Wahba, M., Soliman, S., Salama, M., Nasr, S., & Al Shereef, Z. (2024). PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study. Asian Pacific Journal of Cancer Prevention, 25(4), 1441-1450. doi: 10.31557/APJCP.2024.25.4.1441
MLA
Maha Gamal Wahba; Soliman Saba Soliman; Maha Elsayed Salama; Sarah Nasr; Zeinab Abd El -Azeem Al Shereef. "PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study". Asian Pacific Journal of Cancer Prevention, 25, 4, 2024, 1441-1450. doi: 10.31557/APJCP.2024.25.4.1441
HARVARD
Wahba, M., Soliman, S., Salama, M., Nasr, S., Al Shereef, Z. (2024). 'PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study', Asian Pacific Journal of Cancer Prevention, 25(4), pp. 1441-1450. doi: 10.31557/APJCP.2024.25.4.1441
VANCOUVER
Wahba, M., Soliman, S., Salama, M., Nasr, S., Al Shereef, Z. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study. Asian Pacific Journal of Cancer Prevention, 2024; 25(4): 1441-1450. doi: 10.31557/APJCP.2024.25.4.1441
)